Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Zydus Lifesciences Limited

https://www.zyduslife.com/index

Latest From Zydus Lifesciences Limited

Torrent’s $245m Curatio Deal Gives Pole Position In Fast-Growing Cosmetic Dermatology

Torrent’s $245m acquisition of Curatio Healthcare has moved it up a rank to No.7 in the overall Indian pharmaceutical market apart from making it the market leader in cosmetic dermatology. While it’s a pricey deal, factors like growing prevalence of skin diseases and shift towards e-commerce bode well for future revenue growth in a nascent market

Commercial Deals

Does Zydus’ Promising CAPS Candidate Have An Edge Over Novartis’ Ilaris?

Zydus has established proof of concept for ZYIL1, a NLRP3 inflammasome inhibitor to treat cryopyrin-associated periodic syndromes, via Phase II trials in Australia. Will the oral drug have an upper hand over injectables like Novartis’ Ilaris?

Research & Development Rare Diseases

Monkeypox Vaccines – Golden Opportunity Or False Dawn?

While Moderna plans preclinical studies and Tonix Pharma’s candidate is to enter trials in H1, Bavarian Nordic is seeking US and Indian manufacturing partners for its approved monkeypox vaccine. Scrip examines if the disease presents an opportunity for vaccine makers, like COVID-19 did or it could go the H1N1 way

Commercial Business Strategies

Why India Pharma Failed To Impress In 2020-22 Bull Run

Most Indian pharma stocks, including large firms, yielded double digit negative returns over the last 12 months while the overall market (Bombay Stock Exchange Sensex) delivered positive returns, a new study by an investment banking and consulting services firm indicates. The prognosis for fiscal years 2023/24, though, is optimistic.

Commercial India
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs
    • OTC, Consumer
  • Other Names / Subsidiaries
    • Cadila Healthcare
    • Zydus Pharmaceuticals USA
    • German Remedies
    • Zynesher Pharmaceuticals USA LLC
    • Nesher Pharmaceuticals Inc
    • Quimica e Farmaceutica Nikkho do Brasil Ltda
    • Bremer Pharma GmbH
    • Nippon Universal Pharmaceuticals
    • Zydus Discovery DMCC
    • Zydus Urosciences
    • Sentynl Therapeutics, Inc
    • Zydus Lifesciences Ltd
    • Cadila Healthcare Ltd.
    • Zydus Cadila
UsernamePublicRestriction

Register